Evommune, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-07-29: Study NCT07616128; Company role Lead sponsor; Phase Phase 2; Status Recruiting.
- 2025-08-26: Study NCT07150845; Company role Lead sponsor; Phase Phase 2; Status Active not recruiting.
- 2025-03-20: Study NCT06873516; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2025-02-13: Study NCT06723405; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-07-29 | NCT07616128 Study of EVO756 in Adults With Migraine | Lead sponsor | Phase 2 | Recruiting | Migraine | 330 | 2027-11 |
| 2025-08-26 | NCT07150845 Phase 2b Study of EVO756 in Adults With Atopic Dermatitis | Lead sponsor | Phase 2 | Active not recruiting | Atoptic Dermatitis | 120 | 2026-07 |
| 2025-03-20 | NCT06873516 Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) | Lead sponsor | Phase 2 | Completed | Chronic Spontaneous Urticaria | 182 | 2026-06-05 |
| 2025-02-13 | NCT06723405 Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis | Lead sponsor | Phase 2 | Completed | Atopic Dermatitis (AD); Eczema; Eczema Atopic Dermatitis | 71 | 2025-11-17 |
| 2024-12-03 | NCT06645821 Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1% | Collaborator Lead: Virginia Clinical Research, Inc. | Early Phase 1 | Recruiting | Hidradenitis Suppurativa (HS) | 15 | 2025-05 |
| 2024-08-14 | NCT06603220 A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria | Lead sponsor | Phase 2 | Completed Results posted | Chronic Inducible Urticaria | 30 | 2025-05-08 |
| 2022-09-27 | NCT05579899 Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis | Lead sponsor | Phase 2 | Completed Results posted | Atopic Dermatitis Eczema | 119 | 2023-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |